Bristol Gate Capital Partners Inc. Purchases Shares of 118,275 Eli Lilly and Company (NYSE:LLY)

Key Points

• Bristol Gate Capital Partners Inc. has acquired 118,275 shares of Eli Lilly, valued at approximately $97.7 million, making it the firm's 8th largest position at 4.8% of its total investment portfolio.
• Eli Lilly's shares experienced a decline, trading at $759.76, with a market cap of $720.05 billion and a P/E ratio of 61.82, reflecting the company's substantial valuation challenges.
• The company recently announced a quarterly dividend of $1.50 per share, representing an annualized dividend of $6.00 and a yield of 0.79%, with a current payout ratio of 48.82%.

Bristol Gate Capital Partners Inc. purchased a new position in Eli Lilly and Company (NYSE:LLY - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 118,275 shares of the company's stock, valued at approximately $97,685,000. Eli Lilly and Company accounts for approximately 4.8% of Bristol Gate Capital Partners Inc.'s investment portfolio, making the stock its 8th biggest position.

Other large investors have also bought and sold shares of the company. WestEnd Advisors LLC boosted its holdings in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares during the last quarter. Citizens National Bank Trust Department boosted its stake in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new position in Eli Lilly and Company in the first quarter valued at about $40,000. Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company in the fourth quarter valued at about $43,000. Finally, O Brien Wealth Partners LLC boosted its stake in Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after acquiring an additional 12 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded down $3.19 during trading on Wednesday, reaching $759.76. The company had a trading volume of 4,331,834 shares, compared to its average volume of 2,949,040. The company has a fifty day moving average of $774.07 and a two-hundred day moving average of $800.13. The stock has a market capitalization of $720.05 billion, a P/E ratio of 61.82, a price-to-earnings-growth ratio of 1.08 and a beta of 0.40. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The business had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the prior year, the business posted $2.58 EPS. Eli Lilly and Company's revenue for the quarter was up 45.2% on a year-over-year basis. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.79%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on LLY shares. Morgan Stanley reiterated an "overweight" rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price target for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target on the stock. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Finally, UBS Group lowered their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $1,012.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.